Chinese and German researchers suggested that the drug they obtained from 8 medicinal plants could be a "promising herbal treatment for moderate COVID-19". Details on the patented herbal medicine Shufeng Jiedu capsules were published on October 22 by Phytomedicine, a monthly peer-reviewed medical journal.
Stating that there is currently no validated treatment or vaccine for COVID-19, the researchers stated that the use of traditional Chinese herbal medicine to combat the disease has received international attention and is used regularly during the epidemic, especially in China, traditional Chinese medicine methods, SARS in 2003 and 2009 He said it has been used successfully in the treatment of influenza A (H1N1).
The authors said that Shufeng Jiedu capsules, consisting of eight herbs, have been recognized for the treatment of different viral respiratory infectious diseases based on their antiviral, anti-inflammatory and immunomodulatory activities against acute lung injury. Antiviral and anti-inflammatory properties of Shufeng Jiedu capsules were confirmed with a mouse model. Network analysis 11 showed that the pathways involved in inflammation and immunomodulation were affected by the bioactive compounds of the capsules.
It shortens the recovery time and reduces the symptoms
The authors investigated data from a clinical pragmatic empirical study of patients diagnosed with COVID-19 to evaluate the clinical efficacy of the capsules and determine the best time to start treatment. Clinical data showed that Shufeng Jiedu capsules added to standard antiviral therapy significantly reduced the clinical recovery time of COVID-19 and fatigue as well as cough days compared to standard antiviral therapy alone. Clinical data have provided some promising evidence that capsules can shorten the symptomatic course of COVID-19 in patients with mild to moderate symptoms. The results showed that administering the capsules immediately after the onset of the first symptoms is beneficial, ”he said.
Chinese International Radio
Be the first to comment